On 18 April 2016, Recipharm announced that it had entered into two separate agreements to acquire pharmaceutical contract development and manufacturing operations (CDMO) from Kemwell. The first acquisition comprises operations in the US and Sweden, and the second acquisition comprises operations in India. The conditions for the first acquisition have now been fulfilled and Recipharm will complete this transaction today. The second acquisition, regarding Kemwell’s pharmaceutical operations in India, is conditional on governmental approvals, and is expected to close before year end. The acquisition now to complete is comprising Cirrus Pharmaceuticals Inc., with operations in the US, with services including development of inhalation, liquid, semi-solid, solid and parenteral products with emphasis on early formulation work as well as development of analytical methods and testing, and Kemwell AB in Sweden, with services primarily including manufacturing of APIs, solids and semi -solid formulations. The sellers of Kemwell’s operations in the US and Sweden are Kemfin Holdings Private Ltd (“Kemfin”) and a minority seller (the “Minority Seller”). Purchase price and issue of shares The acquisition price for Kemwell AB and Cirrus Pharmaceuticals Inc. amounts to approximately USD 85 million (approximately SEK 706 million)[1] (http://file:///G:/Shared/Corporate%20Development/IR/Kalista/Press%2 0 release%20-%20Closing%20EN%2020160523.docx#_ftn1) on a cash and debt free basis. With regard to the estimated net debt of USD 10.2 million (approximately SEK 85 million)(1), the preliminary purchase price amounts to approximately USD 75 million (approximately SEK 621 million)1, of which USD 55 million (approximately SEK 458 million)1 is to be paid through a share issue of class B shares at a subscription price of SEK 145.06 per share, and the remainder in cash. The Board of Directors today, by virtue of the authorisation from the Extraordinary General Meeting on 10 May 2016, resolved on a share issue in kind of 3,159,572 series B shares to the sellers of Kemwell AB. The new shares are expected to be registered with the Swedish Companies Registration Office around 26 May 2016. The cash part of the purchase price for Kemwell AB and Cirrus Pharmaceuticals Inc. preliminarily amounts to approximately USD 19.6 million (approximately SEK 163 million)(1). Kemfin and the Minority Seller have undertaken not to sell or in other respects transfer their respective shareholdings in Recipharm in respect of the share issue in kind during a period of 12 months from the closing date. Directed share issue in cash As previously announced, Kemfin and the Minority Seller, provided they receive shares in the issue in kind as described above prior to the record date 23 May 2016 in the ongoing rights issue of Recipharm, have agreed to participate in the rights issue through the exercise of subscription rights. Since Kemfin and the Minority Seller will not receive any subscription rights in the rights issue, the Board of Directors today, by virtue of the authorisation from the Extraordinary General Meeting on 10 May 2016, resolved on a directed share issue in cash of 631,914 series B shares to the sellers of Kemwell AB at a subscription price of SEK 82 per share, corresponding to the subscription price in the rights issue. At full subscription, the rights issue of approximately SEK 805 million and the directed share issue of approximately SEK 51 million as stated above means that Recipharm will receive a total of approximately SEK 856 million before issue costs. Information on Kemwell AB and Cirrus Pharmaceuticals Inc. The US development business is located in Research Triangle Park, North Carolina and employs just under 50 people (full-time equivalent). There are about 120 customers and services offering include both development capability of inhalation, nasal and transdermal products new to Recipharm, and liquid, semi -solid, solid and parenteral products with emphasis on early formulation work as well as development of analytical methods and testing. Recently, the business has also commissioned a GMP suite allowing for expansion into manufacturing of clinical trial material. The services are provided either on a stand-alone basis or as a more comprehensive pharmaceutical product development program. The Swedish business is located in Uppsala and employs around 240 people (full -time equivalent). It consists of two production units including a fully integrated primary and secondary manufacturing facility dedicated to a limited number of products, based on the same API and supplied essentially to one Big Pharma customer. There is also a small general pharmaceutical manufacturing unit. Manufacturing services offering include APIs, solids and semi-solid formulations. More than 95 per cent of the Swedish production is exported to over 60 countries including the US and Japan. For the 12-month period ending on 31 December 2015, the US and Swedish businesses reported net sales of SEK 462 million and adjusted EBITDA of SEK 56 million.[2] (http://file:///G:/Shared/Corporate%20Development/IR/Kalista/Press%2 0 release%20-%20Closing%20EN%2020160523.docx#_ftn2) Cost savings and synergies are expected to yield more than SEK 25 million per annum when fully realized, expected in Q4 2017. These cost savings and synergies will be driven by asset rationalization and savings in general within administration activities. The non -recurring costs for implementation are expected to amount to approximately SEK 7 million. For further information please visit www.recipharm.com or contact: Thomas Eldered, CEO, +46 8 602 52 10 Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of Nasdaq Stockholm. This information was submitted for publication on 23 May 2016, at 8:30 am CET. About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 4.6 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the UK and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com ---------------------------------------------------------------------- [1] (http://file:///G:/Shared/Corporate%20Development/IR/Kalista/Press%20release % 20-%20Closing%20EN%2020160523.docx#_ftnref1) Exchange rate of USD/SEK of 8.3331. [2] (http://file:///G:/Shared/Corporate%20Development/IR/Kalista/Press%20release % 20-%20Closing%20EN%2020160523.docx#_ftnref2) Numbers according to local GAAP and adjusted for non-recurring losses of approximately SEK 14 million. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03 www.recipharm.com
Recipharm completes acquisition of Kemwell AB and Cirrus
Top 10 Most Recent News Articles
Duetti, CesiumAstro, and a Busy NYSE Capital Morning
Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....
Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain
A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...
Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach
A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...
Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now
A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...
Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire
A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...
Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap
Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...
Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care
A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...
Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders
Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...
Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens
Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...
Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress
Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...
Continue ReadingTop 5 Most Recently Viewed Articles
BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech
BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...
Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims
Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...
Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE
Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...
Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now
Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...
Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund
Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...
Continue Reading